ProCE Banner Activity

The Nurse’s Role in Counseling Patients Starting BTK Inhibitors

Clinical Thought
How can nurses and other frontline healthcare professionals best counsel patients who are starting BTK inhibitors? In this commentary, I share key safety and adherence considerations to emphasize when educating patients and caregivers.

Released: July 15, 2021

Expiration: July 14, 2022

No longer available for credit.

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Faculty Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, has disclosed that she has received consulting fees from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, and Sanofi.